Kinesio Taping for Neurogenic Bowel Dysfunction in Spinal Cord Injury

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorPamukkale University

About this trial

Neurogenic bowel dysfunction is a common complication of spinal cord injury and may cause constipation, difficulty with defecation, prolonged bowel care, incomplete evacuation, fecal incontinence, and reduced quality of life. This randomized controlled trial aims to evaluate the effectiveness of Kinesio Taping added to a routine bowel management program in adults with spinal cord injury and upper motor neuron-type neurogenic bowel dysfunction.

Thirty participants will be randomly assigned to one of two parallel groups. The control group will receive a routine bowel management program, while the intervention group will receive Kinesio Taping in addition to the routine bowel management program. Kinesio Taping will be applied to the lower abdominal and lumbosacral regions three times per week for 4 weeks.

The primary outcome will be defecation frequency recorded using a 7-day bowel diary. Secondary outcomes will include stool consistency, defecation duration, perceived constipation severity, neurogenic bowel dysfunction severity, and health-related quality of life. Assessments will be performed before and after the 4-week intervention.

Eligibility criteria

Qualifiers

Adults aged 18 years or older with traumatic or nontraumatic spinal cord injury

Neurological level of injury at T12 or above

Upper motor neuron-type neurogenic bowel dysfunction

Duration of spinal cord injury longer than 6 months

Disqualifiers

Age younger than 18 years

Neurological level of injury below T12

Gastrointestinal disease diagnosed before the spinal cord injury, including irritable bowel syndrome or inflammatory bowel disease

History of conservative treatment for neurogenic bowel dysfunction within the previous 6 months

Trial design

Treatments tested in this trial

  • Kinesio Taping
  • Routine Bowel Management Program

Treatment groups

30 Participants
are divided into 2 treatment groups

Sponsors and collaborators